The New York City technology and startup ecosystem continues to demonstrate robust momentum, anchored by significant venture capital injections across the biotechnology and financial technology sectors. As the local innovation economy progresses through the fourth quarter, investors are maintaining a strong appetite for category-defining platforms and scientific breakthroughs. The latest venture capital, seed, pre-seed, and angel deals highlight the diverse range of industries driving growth within the five boroughs and beyond.
This ongoing reporting captures the dynamic pulse of metropolitan venture activity, spotlighting companies that are redefining their respective markets. From transformative developments in health technology to cutting-edge cross-border payment infrastructure, founders and investors are continuing to deploy capital into high-potential ventures. Below is a detailed look at the prominent funding rounds shaping the landscape, headlined by a major corporate rebranding and a massive capital raise in the biotech space, alongside an innovative cross-border fintech round.
TriGemX Bio — $94M
In the health technology and biotechnology sectors, TriGemX Bio has emerged from stealth and strategic evolution with a staggering $94 million in new venture funding. The financing round was co-led by a powerhouse syndicate of specialized life sciences investors, including The Column Group, TCG Crossover, and Viking Global Investors. This latest influx of capital brings the company’s cumulative reported equity funding to an impressive $573 million since its inception, cementing its status as one of the most heavily backed scientific ventures originating from the regional ecosystem.
Alongside the financing announcement, the company revealed a major corporate evolution. Formerly known to the industry as Kallyope, the enterprise has officially rebranded and relaunched under the new name TriGemX Bio. This strategic renaming reflects the company’s sharpening focus on its core clinical pipeline and its mission to deliver groundbreaking therapeutic solutions to patients suffering from debilitating neurological conditions.
TriGemX Bio was originally founded in 2015 by a trio of distinguished scientific luminaries: Charles Zuker, Richard Axel, and Thomas Maniatis. Their foundational vision was to leverage cutting-edge insights into biological systems to discover and develop innovative medicines. With this fresh capital injection and the newly minted TriGemX Bio identity, the company is advancing its flagship development program: a first-in-class oral medicine specifically designed for the treatment and management of migraines.
Migraines affect hundreds of millions of people globally, often causing severe, debilitating pain and significantly impairing quality of life. Traditional acute and preventative therapies often come with limitations regarding efficacy, side effect profiles, or routes of administration. TriGemX Bio’s first-in-class oral medication aims to address these critical gaps by offering a targeted, patient-friendly therapeutic option born from rigorous, foundational biological research. The participation of premier venture firms like The Column Group, TCG Crossover, and Viking Global Investors underscores the high conviction institutional investors hold in the scientific rigor of the founding team and the commercial potential of the company’s oral migraine treatment pipeline.
Walapay — $4.6M
Shifting from the life sciences to the financial technology arena, Walapay has successfully secured $4.6 million in a seed funding round to accelerate the development of its core payments infrastructure. The round was led by Generative Ventures, with participation from a diverse and strategic group of institutional investors and venture funds, including Commerce Ventures, Polygon Labs, Verda Ventures, NGC Ventures, FGV Capital, Jsquare, Knollwood Investment Advisory, Big Brain Holdings, Reflexive Capital, and Contribution Capital.
Founded in 2022 by industry entrepreneurs Tom Borgers and Dimitri Borgers, Walapay operates at the intersection of traditional finance and modern digital rails. The company addresses the complex pain points associated with global commerce by providing a comprehensive, single-API platform. This unified infrastructure empowers businesses to seamlessly execute account issuance, handle collections, manage currency exchange, and disburse payouts across international borders.
In an increasingly globalized economy, businesses of all sizes frequently struggle with the friction, high costs, and operational inefficiencies of legacy cross-border payment systems. Fragmented banking relationships and outdated technological stacks often slow down international transactions and hinder expansion. Walapay’s single-API approach is designed to abstract away this complexity, offering a streamlined solution that allows enterprises to manage their global financial workflows through one cohesive integration.
The participation of notable investors such as Commerce Ventures, which specializes in financial technology, alongside Web3-focused funds like Polygon Labs and Generative Ventures, highlights the broad applicability of Walapay’s infrastructure across both traditional fiat and emerging digital asset ecosystems. With this $4.6 million seed capital infusion, Walapay is well-positioned to expand its engineering capabilities, scale its operational footprint, and further refine its cross-border payment technology to meet the growing demand for frictionless global commerce solutions.
